Trials / No Longer Available
No Longer AvailableNCT02174679
68Ga DOTATATE PET/CT in Neuroendocrine Tumors (Expanded Access)
68Ga-DOTATATE Imaging in Neuroendocrine Tumors
- Status
- No Longer Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Jonsson Comprehensive Cancer Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
To evaluate 68Ga-DOTATATE PET/CT for staging of patients with carcinoid, neuroendocrine tumors, medullary thyroid cancer and other cancers expressing somatostatin receptors.
Detailed description
This is an expanded access study with a total of 300 participants with NET and suspected SSTR positive tumors. Eligible participants will undergo baseline assessments at enrollment. Study participants will receive 68Ga-DOTATATE and will undergo a PET/CT imaging study. All patients referred by Oncologists will be screened by a UCLA Nuclear Medicine physician and then accepted for scanning if clinically appropriate.
Conditions
- Carcinoid Cancer
- Neuroendocrine Tumors
- Medullary Thyroid Cancer
- Cancers Expressing Somatostatin Receptors
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 68Ga DOTATATE | Patients with somatostatin receptor positive tumors will be evaluated with 68Ga-DOTATATE PET/CT. |
Timeline
- First posted
- 2014-06-25
- Last updated
- 2020-07-27
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02174679. Inclusion in this directory is not an endorsement.